scholarly journals Mechanisms of Reactive Oxygen Species Generated by Inorganic Nanomaterials for Cancer Therapeutics

2021 ◽  
Vol 9 ◽  
Author(s):  
Lizhen Zhang ◽  
Chengyuan Zhu ◽  
Rongtao Huang ◽  
Yanwen Ding ◽  
Changping Ruan ◽  
...  

Recently, inorganic nanomaterials have received considerable attention for use in biomedical applications owing to their unique physicochemical properties based on their shapes, sizes, and surface characteristics. Photodynamic therapy (PDT), sonodynamic therapy (SDT), and chemical dynamic therapy (CDT), which are cancer therapeutics mediated by reactive oxygen species (ROS), have the potential to significantly enhance the therapeutic precision and efficacy for cancer. To facilitate cancer therapeutics, numerous inorganic nanomaterials have been developed to generate ROS. This mini review provides an overview of the generation mechanisms of ROS by representative inorganic nanomaterials for cancer therapeutics, including the structures of engineered inorganic nanomaterials, ROS production conditions, ROS types, and the applications of the inorganic nanomaterials in cancer PDT, SDT, and CDT.

2021 ◽  
Vol 9 ◽  
Author(s):  
Yingbo Li ◽  
Jie Yang ◽  
Xilin Sun

Nanotechnology advances in cancer therapy applications have led to the development of nanomaterials that generate cytotoxic reactive oxygen species (ROS) specifically in tumor cells. ROS act as a double-edged sword, as they can promote tumorigenesis and proliferation but also trigger cell death by enhancing intracellular oxidative stress. Various nanomaterials function by increasing ROS production in tumor cells and thereby disturbing their redox balance, leading to lipid peroxidation, and oxidative damage of DNA and proteins. In this review, we outline these mechanisms, summarize recent progress in ROS-based nanomaterials, including metal-based nanoparticles, organic nanomaterials, and chemotherapy drug-loaded nanoplatforms, and highlight their biomedical applications in cancer therapy as drug delivery systems (DDSs) or in combination with chemodynamic therapy (CDT), photodynamic therapy (PDT), or sonodynamic therapy (SDT). Finally, we discuss the advantages and limitations of current ROS-mediated nanomaterials used in cancer therapy and speculate on the future progress of this nanotechnology for oncological applications.


2017 ◽  
Author(s):  
Shinya Nishitaka ◽  
Daisaku Mashiko ◽  
Ryosuke Iwasaki ◽  
Shin Yoshizawa ◽  
Shin-ichiro Umemura

2015 ◽  
Vol 17 (38) ◽  
pp. 24937-24943 ◽  
Author(s):  
Tao Wen ◽  
Weiwei He ◽  
Yu Chong ◽  
Yi Liu ◽  
Jun-Jie Yin ◽  
...  

Pd nanostructures can promote the decomposition of H2O2 in a pH-dependent manner and scavenge superoxide and singlet oxygen.


2013 ◽  
Vol 2 (6) ◽  
pp. 908-915 ◽  
Author(s):  
Sue Hyun Lee ◽  
Mukesh K. Gupta ◽  
Jae Beum Bang ◽  
Hojae Bae ◽  
Hak-Joon Sung

Polymers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 4418
Author(s):  
Hyun-Chul Kim ◽  
Eunjoo Kim ◽  
Se Guen Lee ◽  
Sung Jun Lee ◽  
Sang Won Jeong ◽  
...  

Reactive oxygen species (ROS)-responsive nanocarriers have received considerable research attention as putative cancer treatments because their tumor cell targets have high ROS levels. Here, we synthesized a miktoarm amphiphile of dithioketal-linked ditocopheryl polyethylene glycol (DTTP) by introducing ROS-cleavable thioketal groups as linkers between the hydrophilic and hydrophobic moieties. We used the product as a carrier for the controlled release of doxorubicin (DOX). DTTP has a critical micelle concentration (CMC) as low as 1.55 μg/mL (4.18 × 10−4 mM), encapsulation efficiency as high as 43.6 ± 0.23% and 14.6 nm particle size. The DTTP micelles were very responsive to ROS and released their DOX loads in a controlled manner. The tocopheryl derivates linked to DTTP generated ROS and added to the intracellular ROS in MCF-7 cancer cells but not in HEK-293 normal cells. In vitro cytotoxicity assays demonstrated that DOX-encapsulated DTTP micelles displayed strong antitumor activity but only slightly increased apoptosis in normal cells. This ROS-triggered, self-accelerating drug release device has high therapeutic efficacy and could be a practical new strategy for the clinical application of ROS-responsive drug delivery systems.


2020 ◽  
Vol 1 (3) ◽  
pp. 2000065
Author(s):  
Wee Kong Ong ◽  
Xuemei Yao ◽  
Deblin Jana ◽  
Menghuan Li ◽  
Yanli Zhao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document